Careteq Limited (ASX:CTQ), a clinical healthtech company, has disclosed that the Australian Taxation Office has disallowed its objections to amended assessments relating to Research and Development Tax Incentive claims for the financial years ended 30 June 2021, 2022, and 2023, and that the company's board has resolved to apply to the Administrative Review Tribunal for a review of the ATO's decision.

Key Points

  • The ATO has disallowed Careteq's objections to amended assessments issued in late May 2025 concerning R&D Tax Incentive claims for FY2021, FY2022, and FY2023.
  • The board, on advice from legal counsel MinterEllison, disagrees with the ATO's decision and maintains its conviction that the R&D activities were eligible and the claims valid.
  • Careteq has resolved to apply to the Administrative Review Tribunal, an independent body, for a review of the ATO's decision.
  • The application to the ART is expected to be lodged within the next few weeks, with the timing of a resolution not yet determined.

ATO Objection Decision on R&D Tax Incentive Claims

Careteq disclosed that it has received the ATO's Notice of Decision on its objections to the amended assessments that were issued in late May 2025, which the company had previously announced on 29 May 2025. The ATO's amended assessments related to the company's Research and Development Tax Incentive claims covering three financial years: those ended 30 June 2021, 30 June 2022, and 30 June 2023. The ATO has disallowed the objections lodged by Careteq in response to those amended assessments, according to the company's filing dated 20 November 2026.

Board Decision to Pursue Administrative Review Tribunal

Following receipt of the ATO's decision, Careteq's board considered the matter with its legal advisers, MinterEllison, and resolved to apply to the Administrative Review Tribunal for a review of the ATO's decision. The filing states that the ART is an independent body that will reconsider the matter on its merits. The company said the application will be lodged over the next few weeks. Careteq also disclosed that the board, on the advice of MinterEllison, disagrees with the ATO's decision and maintains its strong conviction that the company's R&D activities were eligible and that its R&D Tax Incentive claims for the relevant years are valid.

Resolution Timeline and Disclosure Obligations

Careteq stated in the filing that the timing of a resolution to the dispute cannot yet be determined. The board indicated it will keep the market informed of material developments in line with its continuous disclosure obligations. No financial figures relating to the quantum of the amended assessments or the R&D Tax Incentive claims were disclosed in the filing. The company described itself as an Australian healthtech company delivering AI-enabled clinical healthcare solutions, with a wholly owned marketplace platform, HMR Referrals, which streamlines the process of completing Home Medicines Reviews.